Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Listeria-based HPV-16 E7 vaccines limit autochthonous tumor growth in a transgenic mouse model for HPV-16 transformed tumors.

Literature DB >> 18680778

Listeria-based HPV-16 E7 vaccines limit autochthonous tumor growth in a transgenic mouse model for HPV-16 transformed tumors.

Duane A Sewell¹, Zhen Kun Pan, Yvonne Paterson.

Abstract

We have shown that Listeria-based cancer vaccines inhibit the growth of transplanted tumors in a transgenic mouse model of immune tolerance where HPV-16 E7 is expressed in the thyroid gland. In this study we determine whether these vaccines are able to inhibit autochthonous tumor growth in this animal model. Mice treated with Listeria vaccines expressing E7 had significantly smaller thyroid tumors than did mice treated with controls and possessed higher numbers of antigen-specific CD8(+) T cells within the spleens, tumors, and peripheral blood. This study shows that Listeria-based vaccines are able to slow autochthonous tumor growth and break immunological tolerance.

Entities: CellLine Chemical Disease Gene Species

Mesh：

Substances：

Year: 2008 PMID： 18680778 PMCID： PMC2600657 DOI： 10.1016/j.vaccine.2008.07.036

Source DB: PubMed Journal: Vaccine ISSN： 0264-410X Impact factor: 3.641

17 in total

Review 1. Immune evasion in human papillomavirus-associated cervical cancer.

Authors: Robert W Tindle
Journal: Nat Rev Cancer Date: 2002-01 Impact factor: 60.716

2. Listeria-based vaccines can overcome tolerance by expanding low avidity CD8+ T cells capable of eradicating a solid tumor in a transgenic mouse model of cancer.

Authors: Nicholas C Souders; Duane A Sewell; Zhen-Kun Pan; S Farzana Hussain; Alexander Rodriguez; Anu Wallecha; Yvonne Paterson
Journal: Cancer Immun Date: 2007-02-06

3. Two Listeria monocytogenes vaccine vectors that express different molecular forms of human papilloma virus-16 (HPV-16) E7 induce qualitatively different T cell immunity that correlates with their ability to induce regression of established tumors immortalized by HPV-16.

Authors: G R Gunn; A Zubair; C Peters; Z K Pan; T C Wu; Y Paterson
Journal: J Immunol Date: 2001-12-01 Impact factor: 5.422

Review 4. Immunity to intracellular bacteria.

Authors: S H Kaufmann
Journal: Annu Rev Immunol Date: 1993 Impact factor: 28.527

Review 5. The pathogenesis of advanced cervical cancer provides the basis for an empirical therapeutic vaccine.

Authors: S J Ghim; J Sundberg; G Delgado; A B Jenson
Journal: Exp Mol Pathol Date: 2001-12 Impact factor: 3.362

6. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers.

Authors: M L Gillison; W M Koch; R B Capone; M Spafford; W H Westra; L Wu; M L Zahurak; R W Daniel; M Viglione; D E Symer; K V Shah; D Sidransky
Journal: J Natl Cancer Inst Date: 2000-05-03 Impact factor: 13.506

Review 7. Listeria monocytogenes as a vector for tumor-associated antigens for cancer immunotherapy.

Authors: Reshma Singh; Yvonne Paterson
Journal: Expert Rev Vaccines Date: 2006-08 Impact factor: 5.217

8. Regression of HPV-positive tumors treated with a new Listeria monocytogenes vaccine.

Authors: Duane A Sewell; Dennis Douven; Zhen-Kun Pan; Alex Rodriguez; Yvonne Paterson
Journal: Arch Otolaryngol Head Neck Surg Date: 2004-01

9. A recombinant Listeria monocytogenes vaccine expressing a model tumour antigen protects mice against lethal tumour cell challenge and causes regression of established tumours.

Authors: Z K Pan; G Ikonomidis; A Lazenby; D Pardoll; Y Paterson
Journal: Nat Med Date: 1995-05 Impact factor: 53.440

10. Occasional memory cytotoxic T-cell responses of patients with human papillomavirus type 16-positive cervical lesions against a human leukocyte antigen-A *0201-restricted E7-encoded epitope.

Authors: M E Ressing; W J van Driel; E Celis; A Sette; M P Brandt; M Hartman; J D Anholts; G M Schreuder; W B ter Harmsel; G J Fleuren; B J Trimbos; W M Kast; C J Melief
Journal: Cancer Res Date: 1996-02-01 Impact factor: 12.701

39 in total

Review 1. Listeria and Salmonella bacterial vectors of tumor-associated antigens for cancer immunotherapy.

Authors: Yvonne Paterson; Patrick D Guirnalda; Laurence M Wood
Journal: Semin Immunol Date: 2010-03-17 Impact factor: 11.130

2. A live attenuated Listeria monocytogenes vaccine vector expressing SIV Gag is safe and immunogenic in macaques and can be administered repeatedly.

Authors: Gaia Sciaranghella; Samir K Lakhashe; Mila Ayash-Rashkovsky; Saied Mirshahidi; Nagadenahalli B Siddappa; Francis J Novembre; Vijayakumar Velu; Rama Rao Amara; Chenghui Zhou; Sufen Li; Zhongxia Li; Fred R Frankel; Ruth M Ruprecht
Journal: Vaccine Date: 2010-11-09 Impact factor: 3.641

Review 3. The emerging role of immunotherapy in head and neck squamous cell carcinoma (HNSCC): anti-tumor immunity and clinical applications.

Authors: Panagiota Economopoulou; Christos Perisanidis; Evaggelos I Giotakis; Amanda Psyrri
Journal: Ann Transl Med Date: 2016-05

Listeria-based HPV-16 E7 vaccines limit autochthonous tumor growth in a transgenic mouse model for HPV-16 transformed tumors.

Review 1. Immune evasion in human papillomavirus-associated cervical cancer.

2. Listeria-based vaccines can overcome tolerance by expanding low avidity CD8+ T cells capable of eradicating a solid tumor in a transgenic mouse model of cancer.

3. Two Listeria monocytogenes vaccine vectors that express different molecular forms of human papilloma virus-16 (HPV-16) E7 induce qualitatively different T cell immunity that correlates with their ability to induce regression of established tumors immortalized by HPV-16.

Review 4. Immunity to intracellular bacteria.

Review 5. The pathogenesis of advanced cervical cancer provides the basis for an empirical therapeutic vaccine.

6. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers.

Review 7. Listeria monocytogenes as a vector for tumor-associated antigens for cancer immunotherapy.

8. Regression of HPV-positive tumors treated with a new Listeria monocytogenes vaccine.

9. A recombinant Listeria monocytogenes vaccine expressing a model tumour antigen protects mice against lethal tumour cell challenge and causes regression of established tumours.

10. Occasional memory cytotoxic T-cell responses of patients with human papillomavirus type 16-positive cervical lesions against a human leukocyte antigen-A *0201-restricted E7-encoded epitope.

Review 1. Listeria and Salmonella bacterial vectors of tumor-associated antigens for cancer immunotherapy.

2. A live attenuated Listeria monocytogenes vaccine vector expressing SIV Gag is safe and immunogenic in macaques and can be administered repeatedly.

Review 3. The emerging role of immunotherapy in head and neck squamous cell carcinoma (HNSCC): anti-tumor immunity and clinical applications.

4. Tailored immunotherapy for HPV positive head and neck squamous cell cancer.

Review 5. Current state in the development of candidate therapeutic HPV vaccines.

Review 6. Two is better than one: advances in pathogen-boosted immunotherapy and adoptive T-cell therapy.

Review 7. Novel Therapeutics for Recurrent Cervical Cancer: Moving Towards Personalized Therapy.

Review 8. Emerging human papillomavirus vaccines.

Review 9. ADXS-HPV: a therapeutic Listeria vaccination targeting cervical cancers expressing the HPV E7 antigen.

Review 10. HPV-Associated Head and Neck Cancer: Unique Features of Epidemiology and Clinical Management.